IGMS May 2024 7.500 call
| Previous Close | 0.6000 |
| Open | N/A |
| Bid | 1.3000 |
| Ask | 3.9000 |
| Strike | 7.50 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.6000 - 0.6000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2 |
GuruFocus.comIGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns with EPS Projections Amidst Clinical ...
Comprehensive Analysis of Financial Performance and Pipeline Progress
ZacksIGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
IGM Biosciences (IGMS) delivered earnings and revenue surprises of 1.19% and 30.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireIGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments. “We
